Use of stating for the treatment of metabolic syndrome

Details for Australian Patent Application No. 2004298351 (hide)

Owner Novartis AG

Inventors Bortolini, Michele

Agent Davies Collison Cave

Pub. Number AU-A-2004298351

PCT Pub. Number WO2005/058310

Priority 60/529,831 16.12.03 US

Filing date 15 December 2004

Wipo publication date 30 June 2005

International Classifications

A61K 31/404 (2006.01)

A61K 31/47 (2006.01) - Quinolines

Event Publications

15 June 2006 PCT application entered the National Phase

  PCT publication WO2005/058310 Priority application(s): WO2005/058310

12 March 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004298356-Composition for improving skin, hair and coat health containing flavanones

2004298349-Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia